Antiplatelet and lipid-lowering therapies for the secondary prevention of cardiovascular disease: Are we doing enough?

Andrew Grant

    Research output: Contribution to journalArticlepeer-review

    12 Citations (Scopus)


    OBJECTIVE: To evaluate whether current recommendations with respect to the treatment of dyslipidemias and the use of anti-platelet agents are being applied in the secondary prevention of cardiovascular disease in primary care settings. DESIGN: Descriptive study based on data from the FAMUS (FAmily Medicine, Universite de Sherbrooke) primary care register. SETTING AND PARTICIPANTS: Two-hundred and thirty-three physicians participating in the FAMUS project contributed information from nonpregnant patients over 20 years of age consulting for a periodic health examination between 1992 and 1996. INTERVENTIONS: Data from patients in secondary prevention (those with or having had angina, a previous myocardial infarction, bypass surgery, coronary angioplasty or peripheral vascular disease) were extracted and analyzed. MAIN RESULTS: Of the 52,505 patients in the register, 4315 (8%) were identified as being in secondary prevention. Overall, 53% were noted as receiving an antiplatelet agent while 4% were taking warfarin therapy, Only 64% (2780) had a complete lipid profile on record while 38% were being treated with a hypolipidemic agent. In the treated group, only 30% had a low density lipoprotein cholesterol level below 3.0 mmol/L compared with 22% in the untreated group. CONCLUSIONS: A large number of patients identified as being in secondary prevention were not screened for dyslipidemias, and, of those who were, the majority were undertreated according to current recommendations. Antiplatelet agents were more widely prescribed but potentially underused.

    Original languageEnglish
    Pages (from-to)185-189
    Number of pages5
    JournalCanadian Journal of Cardiology
    Issue number2
    Publication statusPublished - Feb 1999


    Dive into the research topics of 'Antiplatelet and lipid-lowering therapies for the secondary prevention of cardiovascular disease: Are we doing enough?'. Together they form a unique fingerprint.

    Cite this